Glofitamab and pirtobrutinib for relapsed mantle cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a combination of two drugs—glofitamab (given as an infusion) and pirtobrutinib (a pill)—for people with mantle cell lymphoma that has come back or not responded to previous treatment. The goal is to see if the combo works better than either drug alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your mantle cell lymphoma has come back or not responded after at least one prior treatment (like chemo or rituximab).
- You have a tumor that can be measured on a scan (at least 1.5 cm in a lymph node or 1 cm in another area).
- Your blood counts and organ function (kidney, liver) are within a safe range (your doctor will check).
- You have not had a major bleeding problem or a serious heart rhythm issue from a BTK inhibitor (like ibrutinib).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the targeted therapy pirtobrutinib before CAR T-cell treatment (Tecartus) works better for mantle cell lymphoma that has come back or not responded to other treatments. It aims to improve outcomes for patients who are eligible for CAR T-cell therapy.
This Phase 2 trial tests how well two anti-cancer medicines—glofitamab and pirtobrutinib—work for mantle cell lymphoma (MCL) that has not responded well to prior BTK inhibitor therapy. It may help by shrinking the lymphoma after earlier treatment and checking how safe the combination is for people with similar disease history.
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
This trial tests a combination of three drugs (glofitamab, ibrutinib, and obinutuzumab) for people with untreated mantle cell lymphoma. The goal is to see if this combination works better for high-risk or older patients.
This trial tests a combination of three drugs (glofitamab, orelabrutinib, and bortezomib) for people with high-risk mantle cell lymphoma. The goal is to see if the combination works better than standard treatments, and it may be an option if your lymphoma has not responded well or has certain aggressive features.
This Phase 2 trial tests how well the combination of pirtobrutinib and venetoclax works for people with mantle cell lymphoma that has come back or did not respond to treatment. It’s meant to help shrink the lymphoma and improve outcomes after prior therapies.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.